ADC Series (VIII)ADC Clinical Development Strategy:How Antibody–Drug Conjugates Achieve Clinical Success

Executive Summary-ADC clinical development

Antibody–drug conjugates (ADCs) have achieved major advances at the scientific and engineering levels, yet clinical success remains highly variable.

Many ADCs:

• show strong performance in preclinical models

• demonstrate early responses in Phase I trials

• ultimately fail in Phase II or Phase III studies

This indicates that the challenge is not solely molecular design, but rather:

ADC clinical development strategy

Successful ADC programs typically require:

• well-optimized dosing and scheduling

• precise patient selection

• manageable toxicity profiles

• a well-designed regulatory pathway

This article provides a systematic breakdown of these key factors.

1. Where Do ADCs Typically Fail?

Many ADCs do not fail because they are completely ineffective, but because:

• efficacy is inconsistent

• toxicity becomes unacceptable

• trial design fails to demonstrate benefit

Common scenarios include:

Phase I Success, Phase II Failure

Possible reasons:

• incorrect patient population in expansion cohorts

• early responses are not reproducible

• cumulative toxicity emerges over time

Tumor Response Without Survival Benefit

Some ADCs achieve:

• Objective Response Rate (ORR)

  → tumor shrinkage (partial or complete)

However, they fail to improve:

• Progression-Free Survival (PFS)

• Overall Survival (OS)

👉 This is a critical barrier for regulatory approval.

2. Dose Selection: MTD vs OBD

Maximum Tolerated Dose (MTD)

Traditional oncology drug development focuses on:

👉 MTD — the highest dose patients can tolerate

Why MTD May Not Be Ideal for ADCs

ADCs have unique characteristics:

• payloads are highly potent cytotoxic agents

• toxicity may be delayed

• efficacy does not always scale linearly with exposure

👉 Higher doses do not necessarily lead to better outcomes

Optimal Biologic Dose (OBD)

The field is increasingly shifting toward:

👉 OBD — the dose that balances efficacy and safety

OBD considers:

• target engagement

• pharmacodynamics (PD)

• efficacy plateau

Practical Challenges

• pharmacokinetics (PK) variability

• heterogeneous target expression

• inter-patient variability

3. Dosing Schedule: An Underappreciated Variable

Dosing frequency significantly impacts:

• payload exposure

• toxicity accumulation

• tumor killing dynamics

Common Schedules

• every 3 weeks (Q3W)

• weekly dosing

• fractionated dosing

Why Schedule Matters

ADC toxicity can arise from:

• cumulative exposure

• peak concentration

👉 Schedule design is fundamentally an optimization problem:

efficacy vs toxicity

4. Patient Selection: The Central Determinant

Patient selection is one of the most critical factors in ADC clinical development.

Target Expression Threshold

Examples:

• HER2-high vs HER2-low

• Trop-2 expression levels

👉 Incorrect cutoff selection can lead to trial failure

Tumor Heterogeneity

Within a tumor:

• some cells express high target levels

• others express little or none

👉 This reduces overall treatment efficacy

Companion Diagnostics (CDx)

Successful ADC programs often rely on:

• robust diagnostic assays

• reproducible patient stratification

Indication Selection

The same target may behave differently across cancer types.

👉 Biology often outweighs technology

5. Toxicity: The True Limiting Factor

The primary limitation of ADCs is often not efficacy, but:

toxicity ceiling

Common Toxicities

Hematologic Toxicity

• neutropenia

• thrombocytopenia

Liver Toxicity

• elevated ALT / AST

Ocular Toxicity

Interstitial Lung Disease (ILD)

👉 One of the most critical and closely monitored risks in ADC development

Why ADC Toxicity Is Complex

Toxicity may arise from:

• target-dependent effects

• off-target uptake

• payload leakage

• Fc-mediated distribution

Combination Therapy Adds Complexity

👉 Toxicity is often amplified rather than additive

6. Endpoint Selection: A Critical Strategic Decision

In ADC clinical development, endpoint selection directly impacts:

• trial design

• probability of success

• regulatory pathway

Objective Response Rate (ORR)

👉 Proportion of patients with tumor shrinkage

• relatively easier to achieve

• commonly used in early-phase trials

• supports accelerated approval

Progression-Free Survival (PFS)

👉 Time until disease progression or death

• moderate difficulty

• more clinically meaningful

Overall Survival (OS)

👉 Time until death from any cause

• gold standard endpoint

• most difficult to achieve

• requires long follow-up

👉 Common ADC strategy:

• use ORR for accelerated approval

• confirm benefit with PFS / OS

7. Case Study: Enhertu (T-DXd)

The success of Enhertu is not accidental.

Key Factors

High Drug-to-Antibody Ratio (DAR)

👉 Enhances payload delivery

Bystander Effect

👉 Enables killing of neighboring low-expression cells

Appropriate Patient Selection

👉 Breakthrough in HER2-low population

Strong Clinical Execution

• trial design

• dose optimization

• regulatory positioning

👉 Success reflects:

integration of biology, engineering, and clinical strategy

8. The Future: Clinical Strategy as the Key Differentiator

As ADC technology matures, differentiation will no longer rely solely on:

• payload

• linker

• antibody

Instead, success will depend on:

clinical development strategy

Including:

• smarter trial design

• biomarker integration

• combination strategy

From Molecule to Market | LuTra Studio Consulting

ADC clinical development is a cross-functional challenge involving:

• tumor biology

• drug engineering

• clinical strategy

• regulatory planning

Many teams excel in science but lack integrated clinical strategy.

At LuTra Studio, we help teams:

• design patient selection strategies

• optimize dose and schedule

• assess toxicity risks

• define clinical positioning

so that ADC programs are not only scientifically sound, but:

👉 clinically and commercially successful

References

Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N.

Strategies and challenges for the next generation of antibody–drug conjugates.

Nature Reviews Drug Discovery (2017)

Drago, J. Z., Modi, S., & Chandarlapaty, S.

Unlocking the potential of antibody–drug conjugates for cancer therapy.

Nature Reviews Clinical Oncology (2021)